Cambridge, UK; 8th January 2021

Toby Wilson Waterworth (CEO) and David Bennett (COO) of Atlantic Healthcare plc will be attending the 9th annual WuXi Global Forum, 11th-13th January.

The forum is open to all those in the global healthcare industry and takes place at the same time as the invitation-only 39th JP Morgan Healthcare Conference.

The organisers, WuXi AppTec, are a global R&D and manufacturing business supporting the pharmaceutical, biotechnology and medical devices sectors. This year they have chosen the theme of ‘Advancing Breakthroughs for Patients’ and will bring together prominent industry voices to advance the thinking on meeting challenges head on, forging new paradigms and shaping the future of healthcare.

If you are interested in exploring investment, during or around this conference, please email

If you are interested in exploring licensing opportunities, during or around this conference, please email

About Atlantic Healthcare

Atlantic Healthcare plc ( is a rare disease pharmaceutical company acquiring, developing and commercializing therapeutics that address unmet patient needs, specializing in gastroenterology.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug, in development for ulcerative colitis and Crohn’s disease. It also owns renzapride, a novel therapy, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders associated with cystic fibrosis, systemic scleroderma and Parkinson’s disease.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.